Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NYSE /
  3. BMY.NYSE

Bristol-Myers Squibb Company (BMY NYSE) stock market data APIs

$48.27 -2.18(-4.3%) as of July 26, 2024
Price chart is built with Anychart

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company Financial Data Overview

50.45
48.27
-
50.61
47.73
39.0364-60.4205
91 767 M
2 027 M
45 534 M
0.0537
0.439
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'BMY',
Type: 'Common Stock',
Name: 'Bristol-Myers Squibb Company',
Exchange: 'NYSE',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000DQLV23',
ISIN: NULL,
CUSIP: NULL,
CIK: '14272',
EmployerIdNumber: '22-0790350',
FiscalYearEnd: 'December',
IPODate: '1972-01-01',
InternationalDomestic: 'International/Domestic',
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - General',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Bristol-Myers Squibb Company Fundamental Data is available in our Financial Data APIs

  • Net Revenue 45 534 M
  • EBITDA 18 172 M
  • Earnings Per Share -3.14
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Bristol-Myers Squibb Company Earnings via APIs

  • Latest Release 2024-07-26
  • EPS/Forecast 1.63

Get Bristol-Myers Squibb Company End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Bristol-Myers Squibb Company latest news via APIs

Why Bristol Myers Squibb Jumped Nearly 10% on Friday

Bristol Myers Squibb(NYSE: BMY) shareholders are certainly finishing the trading week on a high note. The drugmaker's stock is up 9.6% as of 1:14 p.m. ET, according to data from S&P Global Market Inte...

Newell Brands, 3M rise; Saia, DexCom fall, Friday, 7/26/2024

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes on Friday: Bristol-Myers Squibb Co. (BMY), up $4.31 to $49.58. The biopharmaceutical company beat analysts' second-quart...
Do you have any questions?
support@eodhistoricaldata.com